© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Evidence for Adverse Effects of High-Dose GC Treatment of Congenital Adrenal Hyperplasia Broadened, Deepened in New Literature Review
May 15, 2025
The most commonly reported adverse effects of high-dose glucocorticoid therapy were on bone health, cardiometabolic function, and height and growth.
Atopic Dermatitis Treatment Caution: Long-Term Oral Corticosteroid Use Ups Cardiovascular and Thrombotic Risks
May 14, 2025
The potential cardiovascular impact of prolonged oral corticosteroid therapy in the AD population observed in this study confirms longstanding cautions.
Semaglutide Linked to Reduced Risk for MACE Months Before Weight Loss Begins: Post Hoc Analysis
May 14, 2025
Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.
Managing Vasomotor Symptoms of Menopause: A Topline Comparison of Treatments
May 13, 2025
Medical and nonpharmacologic treatment options for VMS range in efficacy and risk/benefit profile; a short slide show offers a topline look at how many compare.
Vasomotor Symptoms of Menopause: Facts At-a-Glance for Primary Care
May 13, 2025
Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.
A Half Dose of Semaglutide Yields Weight Loss Equivalent to Clinical Trial Doses in Combination with Online Support Program
May 13, 2025
Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.
FDA Approves First At-Home Pap Smear Alternative for Cervical Cancer Screening, from Teal Health
May 12, 2025
The Teal Wand allows women to collect a vaginal sample in the privacy of their home and, according to Teal Health, the test has 96% accuracy for cervical precancer.
Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study
May 12, 2025
Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.
Novel TK1 Inhibitor Demonstrates Rapid, Dose-Dependent Efficacy in Atopic Dermatitis in Ph 1 Trial
May 12, 2025
Adults receiving the highest dose achieved 2 times the reduction in EASI scores vs placebo with responses emerging as early as day 8 of treatment.
Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy
May 12, 2025
The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.